Compile Data Set for Download or QSAR
Report error Found 54 of ph data with Target = 'Beta-lactamase TEM'
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 42 | US9120808, Example 41)
Affinity DataIC50: 0.200nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50: 0.400nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178215(US9120808, Example 58)
Affinity DataIC50: 1.40nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 42 | US9120808, Example 41)
Affinity DataIC50: 1.70nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50: 1.70nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178170(US9120808, Example 49)
Affinity DataIC50: 1.80nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178169(US9120808, Example 48)
Affinity DataIC50: 2.40nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178165(US9120808, Mixture of Example 43 and Example 44)
Affinity DataIC50: 3.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178171(US9120808, Example 50)
Affinity DataIC50: 4.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178201(US9120808, Example 26)
Affinity DataIC50: 9.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178214(US9120808, Example 57)
Affinity DataIC50: 10.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50053173((2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-...)
Affinity DataIC50: 17.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178203(US9120808, Example 34)
Affinity DataIC50: 21.7nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178198(US9120808, Example 18)
Affinity DataIC50: 27.1nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50021959(antibiotic MM 14151 | CHEMBL777 | MM 14151 | clavu...)
Affinity DataIC50: 29.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178200(US9120808, Example 24)
Affinity DataIC50: 30.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178204(US9120808, Example 37)
Affinity DataIC50: 44.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178196(US9120808, Example 16)
Affinity DataIC50: 65.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178182(US9120808, Example 1)
Affinity DataIC50: 66.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178210(US9120808, Example 53)
Affinity DataIC50: 72.8nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178188(US9120808, Example 7)
Affinity DataIC50: 78.4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178185(US9120808, Example 4)
Affinity DataIC50: 89nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178211(US9120808, Example 54)
Affinity DataIC50: 97nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178202(US9120808, Example 32)
Affinity DataIC50: 122nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178191(US9120808, Example 10)
Affinity DataIC50: 140nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178209(US9120808, Example 51)
Affinity DataIC50: 254nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178153(US9120808, Example 36 | US9120808, Example 35)
Affinity DataIC50: 408nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178145(US9120808, Example 28 | US9120808, Example 27)
Affinity DataIC50: 426nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM60600(US9120808, Example 13)
Affinity DataIC50: 639nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178189(US9120808, Example 9 | US9120808, Example 8)
Affinity DataIC50: 828nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178199(US9120808, Example 19)
Affinity DataIC50: 871nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178183(US9120808, Example 2)
Affinity DataIC50: 945nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50021954(UNASYN | 3,3-Dimethyl-4,4,7-trioxo-4lambda*6*-thia...)
Affinity DataIC50: 1.07E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178153(US9120808, Example 36 | US9120808, Example 35)
Affinity DataIC50: 1.56E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178205(US9120808, Example 38a | US9120808, Example 38)
Affinity DataIC50: 1.95E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 2.79E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178207(US9120808, Example 39)
Affinity DataIC50: 4.12E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178194(US9120808, Example 15 | US9120808, Example 14)
Affinity DataIC50: 4.27E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178180(US9120808, Example 59)
Affinity DataIC50: 4.39E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 4.92E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178189(US9120808, Example 9 | US9120808, Example 8)
Affinity DataIC50: 5.64E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178192(US9120808, Example 12 | US9120808, Example 11)
Affinity DataIC50: 5.90E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178192(US9120808, Example 12 | US9120808, Example 11)
Affinity DataIC50: 7.31E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178205(US9120808, Example 38a | US9120808, Example 38)
Affinity DataIC50: 8.02E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178184(US9120808, Example 3)
Affinity DataIC50: 8.39E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178197(US9120808, Example 17)
Affinity DataIC50: 1.33E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178213(US9120808, Example 56)
Affinity DataIC50: 1.78E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178194(US9120808, Example 15 | US9120808, Example 14)
Affinity DataIC50: 1.96E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178208(US9120808, Example 40)
Affinity DataIC50: 2.36E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178145(US9120808, Example 28 | US9120808, Example 27)
Affinity DataIC50: 4.57E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

Displayed 1 to 50 (of 54 total ) | Next | Last >>
Jump to: